SCHEMBL4776434

SCHEMBL4776434

O=C(O)C(=Cc1ccc(Cl)nc1)C(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.47
KCNQ2 O43526 3/20 0.47
NAPRT Q6XQN6 1/20 0.45
TP53 P04637 1/20 0.44
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
NFE2L2 Q16236 2/20 0.40
CES2 O00748 3/20 0.40
CES1 P23141 3/20 0.40
GRM4 Q14833 2/20 0.38
AKR1C1 Q04828 1/20 0.38
KCNE1 P15382 1/20 0.37
KCNQ1 P51787 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776426 1.00 KCNQ3 (0.47) KCNQ3KCNQ2NAPRTTP53LMNA
SCHEMBL9194174 0.79 KCNQ3 (0.44) KCNQ3KCNQ2NAPRTALDH1A1KMT2A
SCHEMBL4730607 0.78 AKR1C1 (0.59) TP53LMNAALDH1A1MAPTKMT2A
SCHEMBL112002 0.78 AKR1C1 (0.59) TP53LMNAALDH1A1MAPTKMT2A
SCHEMBL112001 0.78 AKR1C1 (0.59) TP53LMNAALDH1A1MAPTKMT2A
SCHEMBL4777757 0.77 ALDH1A1 (0.43) TP53LMNAALDH1A1MAPTKMT2A
SCHEMBL4777769 0.77 ALDH1A1 (0.43) TP53LMNAALDH1A1MAPTKMT2A
SCHEMBL4777717 0.75 RAB9A (0.56) LMNAALDH1A1MAPTKMT2AGAA
SCHEMBL4777727 0.75 RAB9A (0.56) LMNAALDH1A1MAPTKMT2AGAA
SCHEMBL15758231 0.74 AKR1C3 (0.52) KCNQ3KCNQ2NAPRTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459451-B2 e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease ASTELLAS PHARMA INC. (JP) 2008-12-02 US disclosed
EP-1763528-B1 PYRAZOLOPYRIDINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-11-26 EP disclosed
EP-1763528-A1 PYRAZOLOPYRIDINE DERIVATIVES Astellas Pharma Inc. (JP) 2007-03-21 EP disclosed
WO-2006004188-A1 PYRAZOLOPYRIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2006-01-12 WO disclosed
US-20060004003-A1 Pyrazolopyridine derivatives ASTELLAS PHARMA INC. (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004003-A1 Pyrazolopyridine derivatives PDE4A, PDE3B, PDE5A KCNQ3 334/4885KCNQ2 376/4885NAPRT 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.